Skip to content

Comparision of effects of fluoxetine in different dose on the secondary prevention of patients in acute ischemic stroke: a randomized controlled trial

Comparision of effects of fluoxetine in different dose on the secondary prevention of patients in acute ischemic stroke:a randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15007651
Enrollment
Unknown
Registered
2015-12-26
Start date
2015-12-26
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Group of fluoxetine used in 20mg per day: fluoxetine used in 20mg per day
Group of fluoxetine used in 10mg per day:fluoxetine used in 10mg per day

Sponsors

The Shenzhen People's hospital, Shenzhen, Guangdong, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Adherence to the diagnostic criteria of ischemic stroke as defined by World Health Organization (WHO); (2) first onset of stroke within 1 week; (3) 18–80 years old; (4) symptoms of defective nervous system and National Institutes of Health Stroke Scale (NIHSS) score > 2; and (5) informed consent was obtained from all the patients or their legal relatives.

Exclusion criteria

Exclusion criteria: (1) Hemorrhagic stroke; (2) coma; (3) obvious symptoms of defective nervous system before the onset of stroke; (4) existed self-injurious or suicidal tendency, and needed antidepressants urgently; (5) used antidepressants within 3 months before the onset or benzodiazepines within 2 weeks before the onset; (6) serious heart diseases, respiratory failure, malignant tumor; (7) active peptic ulcer or other gastrointestinal diseases, which may affect the absorption of drugs; (8) liver enzymes or creatinine were abnormal; (9) pregnant or lactating women; (10) severe mental disorders, such as schizophrenia; (11) allergic constitution; (12) participated in other clinical studies within 3 months before the study; and (13) planned to receive endovascular treatment.

Design outcomes

Primary

MeasureTime frame
NIHSS score;

Secondary

MeasureTime frame
BI score;Blood glucose;Blood lipids;Blood pressure;Stroke recurrence;Relative drug side effects;

Countries

China

Contacts

Public ContactGuo Yi
heyitaovv@126.com+86 13590419894

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026